Mercer Global Advisors Inc Summit Therapeutics Inc. Transaction History

Mercer Global Advisors Inc

$43 Billion
Q1 2025

A detailed history of Mercer Global Advisors Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Mercer Global Advisors Inc holds 37,395 shares of SMMT stock, worth $737,055. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,395

Previous 44,678 16.3%

Holding current value

$737,055

Previous $797,000 9.54%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$16.65 - $23.76 $121,261 - $173,044	-7,283 Reduced 16.3%	37,395 $721,000
Q4 2024 Feb 14, 2025	SELL	$17.52 - $23.46 $2,295 - $3,073	-131 Reduced 0.29%	44,678 $797,000
Q3 2024 Nov 13, 2024	SELL	$6.89 - $31.93 $16,825 - $77,973	-2,442 Reduced 5.17%	44,809 $981,000
Q2 2024 Aug 12, 2024	SELL	$2.39 - $10.92 $4,662 - $21,304	-1,951 Reduced 3.97%	47,251 $368,000
Q1 2024 May 15, 2024	BUY	$2.55 - $5.07 $2,300 - $4,573	902 Added 1.87%	49,202 $204,000
Q2 2023 Aug 14, 2023	BUY	$1.32 - $2.81 $6,864 - $14,612	5,200 Added 12.06%	48,300 $121,000
Q4 2022 Feb 08, 2023	BUY	$0.68 - $5.31 $544 - $4,248	800 Added 1.89%	43,100 $183,000
Q3 2022 Nov 15, 2022	BUY	$0.89 - $1.63 $1,869 - $3,423	2,100 Added 5.22%	42,300 $50,000
Q2 2022 Aug 10, 2022	BUY	$0.92 - $2.38 $14,076 - $36,414	15,300 Added 61.45%	40,200 $40,000
Q1 2022 May 10, 2022	BUY	$2.0 - $3.45 $5,900 - $10,177	2,950 Added 13.44%	24,900 $61,000
Q4 2021 Feb 04, 2022	BUY	$2.45 - $5.64 $9,800 - $22,560	4,000 Added 22.28%	21,950 $59,000
Q2 2021 Aug 10, 2021	BUY	$5.15 - $8.46 $5,150 - $8,460	1,000 Added 5.9%	17,950 $134,000
Q1 2021 May 11, 2021	BUY	$5.17 - $11.19 $87,631 - $189,670	16,950 New	16,950 $99,000

Others Institutions Holding SMMT

# of Institutions

236

Shares Held

86.8M

Call Options Held

1.84M

Put Options Held

3.13M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.97B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.

Account

Mercer Global Advisors Inc Summit Therapeutics Inc. Transaction History